Gastric Bypass Promotes More Lipid Mobilization Than a Similar Weight Loss Induced by Low-Calorie Diet by Kullberg, Joel et al.
Hindawi Publishing Corporation
Journal of Obesity
Volume 2011, Article ID 959601, 8 pages
doi:10.1155/2011/959601
Research Article
GastricBypass Promotes More Lipid MobilizationThan aSimilar
WeightLoss Induced byLow-CalorieDiet
Joel Kullberg,1 Magnus Sundbom,2 Arvo Haenni,3 Susanne Freden,3 Lars Johansson,1
Peter B¨ ornert,4 AndersAhlstr¨ om,2 H˚ akanAhlstr¨ om,1 and AndersKarlsson5
1Department of Radiology, Uppsala University, 751 85 Uppsala, Sweden
2Department of Surgery, Uppsala University, 751 85 Uppsala, Sweden
3Department of Public Health and Caring Sciences, Uppsala University, 751 85 Uppsala, Sweden
4Philips Research Europe, D-22335 Hamburg, Germany
5Department of Medical Sciences, Uppsala University, 751 85 Uppsala, Sweden
Correspondence should be addressed to Joel Kullberg, joel.kullberg@radiol.uu.se
Received 2 August 2010; Revised 1 October 2010; Accepted 13 October 2010
Academic Editor: Francesco Saverio Papadia
Copyright © 2011 Joel Kullberg et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background. Recently, we found large reductions in visceral and subcutaneous fat one month after gastric bypass (GBP), without
any change in liver fat content. Purpose. Firstly to characterize weight loss-induced lipid mobilization after one month with
preoperative low-calorie diet (LCD) and a subsequent month following GBP, and secondly, to discuss the observations with
reference to our previous published ﬁndings after GBP intervention alone. Methods. 15 morbidly obese women were studied
p r i o rt oL C D ,a tG B P ,a n do n em o n t ha f t e rG B P .E ﬀects on metabolism were measured by magnetic resonance techniques and
blood tests. Results. Body weight was similarly reduced after both months (mean: −8.0kg, n = 13). Relative body fat changes
were smaller after LCD than after GBP (−7.1 ± 3.6% versus −10 ± 3.2%, P = .029, n = 13). Liver fat fell during the LCD month
(−41%, P = .001, n = 13) but was unaltered one month after GBP (+12%). Conclusion. Gastric bypass seems to cause a greater
lipid mobilization than a comparable LCD-induced weight loss. One may speculate that GBP-altered gastrointestinal signalling
sensitizes adipose tissue to lipolysis,promoting the changes observed.
1.Introduction
Gastric bypass (GBP) surgery markedly reduces body weight
with predominant losses of body fat and smaller reductions
of lean body mass and bone mass [1]. The eﬃciency of
GBP in treating morbid obesity is widely recognized, and
its eﬀect to improve glucose intolerance and diabetes is
remarkable. In addition to the caloric restriction imposed
bytheoperation,alteredgastrointestinal hormonalsignalling
[2–4] is generally thought to contribute to the beneﬁcial
eﬀect of GBP in resolving diabetes [5, 6].
In a recent study using magnetic resonance imaging
(MRI) and magnetic resonance spectroscopy (MRS), we
observed a larger relative reduction in visceral fat depot than
subcutaneous fat at one month following GBP, and further-
more, an unexpected lack of change in liver fat [7]. At this
time point, the morbidly obese subjects had lost an average
of four BMIunits, and the insulin sensitivity, as calculatedby
HOMA index, had improved by 34%.Fasting concentrations
of free fatty acids (FFA) and beta-hydroxybutyric acid were
elevated, reﬂecting lipolysis and ﬂux of free fatty acids to
the liver. In general, an inverse relationship between liver
fat content and insulin sensitivity has been described [8, 9].
In this regard, the situation observed one month after GBP
represents a notable disconnect.
Short periods of low-calorie diet (LCD) prior to gastric
bypass are increasingly recommended by surgeons in order
to preoperatively reduce body weight and liver volume and
thereby facilitate the surgical procedure [10, 11]. To provide
further insights into lipid dynamics after GBP, we evaluated
a group of morbidly obese women prior to one month
of preoperative LCD, at surgery, and one month after the
GBP. The metabolic balance was examined by blood tests,
and changes of the lipid depots were analyzed with a novel2 Journal of Obesity
MRI setup, including postprocessing and MRS. Signiﬁcant
diﬀerences between the two treatment periods with respect
to the changes in total amount of body fat as well as liver fat
were observed.
2.Materialsand Methods
2.1. Subjects and Study Design. Fifteen morbidly obese
women with the characteristics summarized in Table 1 were
recruited from the waiting list for laparoscopic gastric
bypass at the Department of Surgery, University Hospital in
Uppsala, Sweden. None of the subjects had a speciﬁc hepatic
disease disorder resulting in fatty liver or a history of alcohol
abuse. The local ethics committee approved the study, and
written consent was obtained from all subjects. This study
wasperformedalsotodeterminetowhatextentaone-month
LCD treatment would reduce liver volume and facilitate the
surgical procedures (to be published).
The study procedures were based on three main visits,
separated by one month. At each of these visits, blood sam-
ples were drawn after overnight fasting. MR investigations
were performed at the same day in a fed state. First visit:
MRI/MRS was carried out in the forenoon, and the LCD
treatment was initiated, after consultation with a dietician,
during the afternoon. To increase motivation and thereby
improve LCD compliance, a meeting with a dietician was
held after approximately one week of LCD. Second visit:
MRI/MRS was performed in the evening and the GBP the
following day. Third visit: MRI/MRS was performed in the
afternoon.
2.2. Low-Calorie Diet. LCD treatment (Modifast, Inpolin
AB, Stockholm) was initiated one month prior to the GBP.
All participants received information and instructions from
thesame physician and atrained dietician. The LCD regimen
ad modum Modifast, containing 30E% protein, 49E%
carbohydrates, and 21E% fat, was prescribed. Total calorie
intake was set to total energy expenditure, as calculated
by Harris-Benedict, minus 1000kcal/day. A lower limit of
860kcal/day was used. The resulting total calorie intake
averaged 959 ± 149kcal/day.
2.3. Surgery. Laparoscopic gastric bypass surgery was per-
formed at the Department of Surgery, Uppsala University
Hospital according to clinical routine [12]. A ﬁve-port
techniquewithcircularstaplingofthegastrojejunostomywas
used. The proximal jejunum was divided 30cm distal to the
ligament of Treitz, and a 70-cm Roux-limb was created. The
small bowel continuity was restored by an enteroanastomo-
sis. The left liver lobe was then elevated by an Endopaddle
(Ethicon Endosurgery, Johnson&Johnson, Cincinnati, OH).
The angle of His was opened as well as the bursa ﬁve
cm distal to the gastroesophageal junction on the lesser
curvature. The pouch was divided by a horizontal 45mm
cutting linear stapler and two vertical 60mm rows. The anvil
of the 25mm circular stapler was passed transorally and
placed in the right-angled corner in-between the two ﬁrst
stale lines. The Roux-limb was passed anticolic, antigastric
and anastomosed to the pouch end-to-side by the circular
s t a p l e r( C o v i d i e n ,N o r w a l k ,C T ) .F i n a l l y ,t h ea n a s t o m o s i s
was checked by air under water, and the portholes were
closed. The patients were given preoperative antibiotics and
thromboprophylaxis by subcutaneouslow-molecular-weight
heparin (LMWH) for 14 days. In each recruited patient, the
laparoscopic gastric bypasses could be performed and the
postoperative course was uneventful, except in one patient
who had the enteroanastomosis corrected.
2.4. Blood Analyses. Blood was collected after an overnight
fast, and serum and plasma were prepared and stored
at −70◦C until analysis. Fasting plasma glucose, total
cholesterol, low-density lipoprotein (LDL) cholesterol, high-
density lipoprotein (HDL) cholesterol, triglycerides (TG),
free fatty acids (FFA), apolipoproteins A1 and B, and
liver enzymes were measured with routine laboratory tech-
niques.Insulin was analyzed with an AutoDELFIAautomatic
immunoassay system (Wallac Oy, Turku, Finland). Growth
hormone (GH), glucagons, and NT-pBNP were determined
with assays in routine use at Clinical Chemistry, Uppsala
University Hospital. Beta-hydroxybutyrate was spectropho-
tometrically determined in plasma with an enzymatic end-
point method [13]. Leptin and adiponectin were analyzed in
plasma samples as previously described [14]. The homeosta-
sismodelassessment (HOMA,mmol/L)indexwascalculated
by multiplying fasting plasma glucose mmol/L and fasting
insulin mU/L and then dividing by 22.5 [15].
2.5. Magnetic Resonance Acquisition. The MR measurements
were performed using a 1.5T clinical scanner (Achieva;
Philips Healthcare, Best, The Netherlands) modiﬁed to allow
imaging during arbitrary table speed. A special 3D gradient
echo sequencewas used to collect three images with diﬀerent
echotimes(TE)fromeachaxialsliceduringcontinuoustable
motion [16]. Imaging parameters were as follow: TR 5.9ms,
TE 1.36/3.22/5.09ms, ﬂip angle 3 degrees, elementary signal
sampling ﬁeld of view (FOV) (in motion direction) 112mm,
virtualFOV530×377×2000mm3,andvoxelsize2.07×2.07×
8.00mm3. The table speed was set to 6.5mm/s resulting in
a whole-body scan time of 5min, 15sec. Shallow breathing
was instructed during acquisition of the abdominal region
to reduce potential respiration inducing motion artefacts.
Subjects were imaged in supine position with the arms
extended above the head.
To evaluate liver fat, single-volume localized 1H-
spectroscopy was performed in a 3 × 3 × 3c m 3 volume of
interest positioned in the right liver lobe, avoiding major
vessels and bileducts. A PRESS acquisition was used with the
parameters TR/TE, 3000/44ms, with 16 excitations without
water suppression and 32 with water suppression (1024
samples, 1000Hz bandwidth) during free shallow breathing.
2.6. Magnetic Resonance Data Processing. Whole-body water
and fatimages were reconstructedusing themultiechoimage
data as previously described [17]; see Figure 1.V i s c e r a l
and abdominal subcutaneous adipose tissue (VAT and SAT)
was automatically measured from the reconstructed waterJournal of Obesity 3
Table 1: Subject characteristics of the 15 females at baseline and after one month of low-calorie diet (LCD) and one month after gastric
bypass (GBP).
Baseline Post LCD Post GBP
Mean ± SD Mean ± SD P value Mean ± SD P value
Age (years) 34.7 ±7.88
Weight (kg) 121.3 ±13.4 113.9 ±12.0 <.001 105.8 ± 12.0 <.001
BMI (kg/m2)4 2 .9 ± 3.02 40.3 ±2.93 <.001 37.4 ± 2.99 <.001
Total fat Volume (L) 69.3 ±7.55
a 64.3 ± 6.85
a <.001 58.0 ±7.65
a <.001
Total water Volume (L) 42.9 ±4.53 a 40.8 ± 3.82 a <.001 38.8 ±4.44 a <.001
VAT (L) 5.31 ±0.97 a 4.91 ± 0.88 a .002 4.39 ±0.73 a <.001
SAT abd (L) 21.3 ±2.93 a 19.8 ± 2.73 a .003 17.8 ±3.10 a <.001
Liver fat (%) 9.72 ±6.31
a 5.69 ± 4.24
a .001 5.89 ±3.93
a .736
Liver volume (L) 2.17 ±0.38
a 1.90 ± 0.23
a .001 1.89 ±0.28
a .841
Liver fat Volume (mL) 218 ±154 107 ±78.0 <.001 111 ±70.8 .376
Hemoglobin (g/L) 139 ± 7.54 140 ±7.26 .845 136 ±6.77 .099
EVF (%) 41.2 ±2.40 40.8 ±2.51 .458 39.3 ± 2.23 .115
Na (mmol/L) 136 ± 0.99 137 ±1.64 .041 139 ±1.62 .007
K (mmol/L) 3.95 ±0.20 3.67 ±0.25 .009 3.65 ± 0.23 .793
Creatinine (umol/L) 58.9 ±3.75 65.9 ±6.34 .000 58.7 ± 5.90 .003
Albumin (g/L) 41.3 ±2.26 44.5 ±3.23 .001 43.3 ± 2.72 .221
ALT (ukat/L) 0.43 ±0.15 0.93 ±0.60 .007 0.57 ± 0.26 .015
AST (ukat/L) 0.47 ±0.11 0.62 ±0.23 .045 0.48 ± 0.12 .034
GT (µkat/L) 0.65 ±0.72 0.74 ±0.81 .119 0.53 ± 0.28 .179
Glucose (mmol/L) 5.14 ±0.67 4.73 ±0.83 .005 5.03 ± 0.49 .082
Insulin (mU/L) 22.9 ±7.82 17.1 ±8.15 <.001 13.3 ± 5.52 .096
HOMA index 5.32 ±2.18 3.63 ±1.93 <.001 2.99 ± 1.33 .241
Growth hormone (ug/L) 0.46 ±0.52 1.05 ±0.97 .008 1.49 ± 1.11 .146
Glucagon (pmol/L) 73.4 ±20.86 9 .4 ±17.9 .149 75.8 ± 18.2 .024
BNP (ng/L) 44.7 ±27.44 6 .3 ±28.4 .847 93.7 ± 71.5 .011
Leptin (mg/L) 17.4 ±4.91 12.8 ±8.43 .000 10.3 ± 3.29 .001
Adiponectin (Ug/mL) 7.49 ±2.97 8.37 ±8.43 .302 8.13 ± 3.56 .662
Cholesterol (mmol/L) 4.79 ±1.14 4.43 ±1.05 .002 4.29 ± 0.92 .349
HDL (mmol/L) 1.08 ±0.19 0.93 ±0.15 .001 0.95 ± 0.19 .550
LDL (mmol/L) 3.07 ±0.96 2.85 ±1.05 .125 2.64 ± 0.84 .145
LDL/HDL 2.93 ±1.10 3.27 ±1.44 .092 2.95 ± 1.05 .094
Triglycerides (mmol/L) 2.17 ±1.28 1.80 ±0.76 .255 1.80 ± 0.54 1.000
ApoA1 (g/L) 1.33 ±0.14 1.10 ±0.12 <.001 1.11 ± 0.11 .829
ApoB (g/L) 0.96 ±0.32 0.89 ±0.28 .048 0.88 ± 0.25 .775
ApoB/ApoA1 0.73 ±0.25 0.82 ±0.28 .014 0.79 ± 0.23 .290
FFA (mmol/L) 0.58 ±0.23 0.85 ±0.33 .011 0.89 ± 0.28 .739
Beta-hydroxybutyrate (mmol/L) 0.07 ±0.05 0.31 ±0.28 .007 0.34 ± 0.22 .613
aData from the 13 subjects who completed the MR investigations. BMI: body mass index, VAT: visceral adipose tissue volume, SAT: subcutaneous adipose
tissue volume in the abdominal subvolume, EVF: erythrocyte volume fraction. ALT: alanine transaminase, AST: aspartate aminotransferase, GT: gamma
glutamyltransferase,BNP: B-type natriuretic peptide, FFA: free fattyacids.
Statisticalsigniﬁcance evaluated from baseline to post-LCD, and post-LCD to post-GBP.
and fat images as previously described [16]. Coeﬃcients of
variation (CVs) of repeated investigations have previously
been determined to be 2.3% ± 2.6% and 2.3% ± 2.1%, for
VAT and SAT, respectively. Estimates of total fat and water
volumes were calculated by summing the signals in the fat
and water fraction images, respectively [16]; see Figure 1.T o
reduce the eﬀect from diﬀerences in the amount of arms
and feet included in the image volumes only, manually
determinedsubvolumes(fromthetopoftheheadtotheaxial
slice above the feet with “smallest areas”) were analyzed. The
fat volume is derived mainly from adipose tissues while the
water volume originates mainly from lean tissue.
Spectroscopy data was analyzed using jMRUI [18]( v e r -
sion 3.0; www.mrui.uab.es), employing water as internal4 Journal of Obesity
(a) (b) (c) (d)
Figure 1: Illustration of image data employed from one subject included in the study. Reconstructed fat and water images are shown
in (a) and (b), respectively. The horizontal lines delineate the subvolumes analysed in (c) and (d), where the fat- [fat/(fat+water)] and
water-fraction [water/(fat+water)] images calculated and used to estimate total fat and water volumes are shown, respectively. Note that the
intensity variations seen in (a) and (b) are removed by the use of fraction images. The intensity in each pixel estimates its absolute fat and
water contents, and by integrating the pixel contents,total volumes are obtained. Note that fatinﬁltration ofthe liver (greyish and measured
to approximately 25%) can be seen in (c).







































liver fat during the LCD and the GBP months (n = 13).
reference, facilitating liver fat measures in percent. Spectral
line intensities were determined by time domain ﬁtting,
using the nonlinear least-squares AMARES algorithm [19].
No spectral preprocessing was applied.
Liver volumes were assessed by manual segmentation
in axial slices of the reconstructed water images by two































Figure 3:Individual totalbody fatvolumesmeasuredusingpriorto
onemonthofLCD,atsurgery, andatonemonthpostGBP (n = 13).
Mean body fat volume is illustrated by the thicker line.
experienced operators using the software ImageJ (version
1.40g, http://rsbweb.nih.gov/ij/). Average liver volumes were
used. The liver fat assessment using MRS gives liver fat
concentration (%). If this concentration changes, one does
not know if that is a result of change in liver fat content or if
the total liver volume has changed for other reasons. Since
liver volume was also assessed in this study, the total liver
fat volume was calculated by multiplying concentration and
volume.
2.7. Statistics Analysis. Two-sided, paired t-tests were used to
test for diﬀerences between absolute values between the timeJournal of Obesity 5


















Figure 4: Liver fat concentrations (%) determined using MRS at
the three time points (n = 13). The thicker line illustrates mean
liver fat concentration.
points in Table 1 and between relative changes in Table 2. P
values of <.05 were considered statistically signiﬁcant.
3.Results
Thepatientslostcomparableamountsofbodyweightduring
the two months, on average 7.47 ± 2.59kg during the ﬁrst
m o n thwi thL C Da n d8 .09±1.70kgduring the postoperative
month (P = .497/.148, for absolute/relative changes, resp.,
n = 15). The weight reductions in 13 subjects successfully
analyzedwithMRI/MRSwere8.03±2.28and8.03±1.76kg,
respectively.Therelativedecreaseintotalbodyfatwasgreater
during the GBP month (from −7.1% ± 3.6% to −10.0 ±
3.2%, P = .029, n = 13). The reductions in the visceral
and abdominal subcutaneous fat depots were on average
−7.3% and −6.6%, respectively, after LCD and −10.3% and
−10.3% after GBP. The estimated water volumes showed
similar changes during the LCD and the GBP month, −4.8%
and −5.0%, respectively.
The measurements at the diﬀerenttime pointsare shown
in Table 1 and the relative changes in Table 2. The MRI/MRS
data is reported for the 13 subjects successfully analysed
at all three time points. One subject cancelled all MR
investigations and another subject cancelled her third. The
relative mean changes in weight, total fat and water volumes
and also in liver fat are shown in Figure 2. The absolute fat
volumes and liver fat measurements are shown in Figures 3
and 4, respectively.
Liver volume decreased signiﬁcantly over the LCD-
month but not during the GBP month. Corresponding
changesin liverfat were determined tobe −40.6% ± 25.3%,
(P = .001) and +12.4% ± 51.7%, (P = .736).
Biochemically, alterations in fasting glucose and insulin
levels took place during the two periods, resulting in
increased insulin sensitivity as reﬂected by the HOMA
indices. Free fatty acids concentrations increased from 0.58
to 0.85mmol/L after LCD and to 0.89mmol/L one month
after the operation. The beta-hydroxybutyrate concentra-
tions increased by several folds during LCD, from a mean of
0.07 to 0.31umol/L and remained elevated one month after
surgery, 0.34umol/L.
The patients studied had, at baseline, cholesterol and
apolipoprotein A and B within the normal reference ranges
and slightly elevated triglycerides. After diet and surgery,
changes within the reference ranges were noted. Leptin fell
during both LCD and GBP. Adiponectin tended to increase
after LCD and was not further altered over the postoperative
month. Mean values of growth hormone prior to LCD, at
surgery, and at one month after GBP were 0.46, 1.05, and
1.49ug/L,glucagon73,69,and76pmol/L,andNT-pBNP45,
46, and 94ng/L, respectively.
Alanine transaminase (ALT) increased after LCD from
0.43 to 0.93µkat/L and fell into the normal range to 0.57 the
month after surgery. Aspartate aminotransferase (AST) and
gamma glutamyltransferase (GT) showed similar patterns of
lesser magnitude.
4.Discussion
The extent of weight loss after the month with LCD and that
attheﬁrstmonthafterGBPweresimilar, yetthemobilization
of body fat was larger after the operation than after the LCD.
Furthermore, the amount of liver fat was not lowered one
month after GBP, which it was after the month of LCD.
Freefatty acidsandthebeta-hydroxybuturateconcentrations
were elevated and tended to be higher one month after
GBP, compared to after one month of LCD. Collectively, the
ﬁndings indicate a more marked ﬂux of fatty acids from the
adiposetissuestotheliverandsubsequentincorporationinto
triglycerides during the month after GBP compared to the
LCD month.
A limitation of the design used in this study is that
the eﬀects seen during the month after GBP are not only
inﬂuenced by the GBP surgery but also by eﬀects of the
preoperativeLCD.Therestrictionofthecaloricintakeduring
the preoperative LCD month most likely reduces the initial
lipolytic eﬀects seen after GBP. Despite this, the results from
the current study indicate instead an increased lipolysis after
GBP.
The observation of unchanged liver fat one month after
surgery is in good agreement with our previous prospective
report on lipid mobilization over a year-long period after
GBP, in which at one month after surgery, there likewise
w a sn oc h a n g ei nl i v e rf a t ,d e s p i t em a r k e dc h a n g e si n
subcutaneous and visceral depots [7]. The patients of the
previous study were also of female gender and had similar
age,weight,andBMI(35yearsrange22–47,122 ±13kg,and
43.7±4.1kg/m 2, resp.) as the subjects of this study. Thereby,
they can be regarded as a historical control group of obese
subjects undergoing gastric bypass without a preoperative
LCD period. These subjects lost, on average, 11.0kg body
weight and 8.4liters of adipose tissue (also assessed using
whole-body MRI) the ﬁrst month after GBP. This should
be compared to the reductions of 7.4kg body weight and
5.0liters of adipose tissue measured after the LCD month
in the current study. It seems likely that the lesser degree of
weight loss during the month after GBP in the present study6 Journal of Obesity
Table 2: Relative changes (%) over the low-calorie diet (LCD) and postGBP periods.
LCD month GBP month P value
Weight / BMI −6.08 ± 1.77 −7.17 ± 1.60 .148
Total Fat Volume −7.11 ± 3.58 a −10.0 ± 3.19 a .029
Total Water Volume −4.82 ± 2.29 a −4.98 ± 2.69 a .898
VAT −7.28 ± 6.92
a −10.3 ± 6.40
a .326
SAT abd −6.55 ± 6.73 a −10.3 ± 5.32 a .171
Liver Fat −40.6 ± 25.3 a +12.4 ± 51.7 a .011
Liver Volume −12.0 ± 7.54 a −0.40 ± 8.33 a .013
Liver Fat Volume −47.2 ± 24.51 3 .6 ± 55.9 .006
Hemoglobin 0.27 ±3.73 −2.72 ±6.17 .195
EVF −0.87 ±5.04 −3.27 ±7.81 .409
Na 0.79 ±1.34 1.32 ±1.62 .473
K −6.78 ±8.83 −0.19 ±10.1 .184
Creatinine 11.9 ±8.32 −10.4 ±11.0 <.001
Albumin 7.84 ±7.08 −2.32 ±7.90 .009
ALT 138 ±180 −26.5 ±29.3 .007
AST 43.1 ±88.2 −16.4 ±25.5 .047
GT 14.9 ±38.1 −3.81 ±39.3 .282
Glucose −8.01 ±8.53 8.01 ±13.2 .008
Insulin −27.0 ±20.1 −12.5 ±43.8 .339
HOMA index −32.2 ±22.2 −2.47 ±60.2 .141
Growth hormone 348 ±621 422 ±1070 .835
Glucagon −3.54 ±17.11 0 .6 ±15.3 .055
BNP 34.1 ±97.5 146 ±173 .078
Leptin −25.7 ±14.6 −18.3 ±19.9 .182
Adiponectin 16.0 ±47.37 6 .8 ±310 .504
Cholesterol −7.11 ±7.31 −2.13 ±11.4 .269
HDL −13.3 ±12.52 .46 ±13.3 .023
LDL −6.91 ±17.1 −5.23 ±15.1 .830
LDL/HDL 12.4 ±21.2 −7.36 ±16.6 .043
Triglycerides −6.01 ±37.87 .10 ±29.7 .409
Ap-lipA1 −16.6 ±8.11 1.09 ±9.80 .001
Ap-lipB −5.97 ±13.00 .15 ±10.8 .268
ApB/A1 15.3 ±20.6 −2.30 ±14.4 .050 (.0497)
FFA 74.4 ±109 20.9 ±589 .186
Beta-hydroxybutyrate 482 ±651 103 ±220 .080
aData from the 13 subjects who completed the MR investigations. BMI: body mass index, VAT: visceral adipose tissue volume, SAT: subcutaneous adipose
tissue volume in the abdominal subvolume, EVF: erythrocyte volume fraction. ALT: alanine transaminase, AST: aspartate aminotransferase, GT: gamma
glutamyltransferase,BNP: B-type natriuretic peptide, FFA: free fattyacids.
Statisticalsigniﬁcance evaluated from diﬀerences in relative changes over the LCD and GBP months.
is inﬂuenced by the prior weight loss that took place during
the preoperative LCD month.
The similar weight losses measured in this study suggest
that the caloric intakes over the two periods were compara-
ble. Average caloric intake three to six months after gastric
bypass surgery has been estimated to be 960–1000kcal/day
[20, 21], that is, close to that of the LCD employed (average
959kcal/day).Thepatientswereadvisedadietwithanenergy
content and macronutrient composition similar to that of
the LCD. After an operation, patients typically take multiple,
small meals in order to lower a risk of dumping and/or
postprandial hypoglycemic episodes. We did not collect
dietary records in attempts to calculate detailed energy,
protein, lipid, and carbohydrate intake.
To account for the larger reduction in fat after GBP
comparedtotheLCDperiod butsimilarweight lossesduring
the two periods, a somewhat larger reduction in nonfat
compartments should have taken place during the LCD
month. With the MRI technique used, only two compart-
ments are visualized as images generated from protons in fat
and water molecules. The fat volumes primarily reﬂect the
adipose tissue eventhough bonemarrow and fatty inﬁltrated
tissues/organs also contribute. The water volumes reﬂect
the nonfat lean tissue of muscles, organs, and brain. BoneJournal of Obesity 7
marrow and water content in adipose tissue also contribute.
In this study, the change in water volumes did not diﬀer
betweenthe LCDand GBPmonths, in contrast tothe change
in fat volumes. A limitation of our study is that we did not
perform any measurements by DEXA, which would provide
information on changes in lean tissue and bone.
There was an increase in liver enzymes during LCD and
a trend towards normalization over the month following
the operation. In general, morbid obesity is associated with
somedegreeofsteatohepatitisandelevationofliverenzymes,
changes that improve upon long-term weight loss [22].
Marked diet-induced weight loss over shorter periods of
time has been found to increase liver enzymes [23, 24]b y
mechanisms that are not fully understood [25]. In some
studies, the increase in enzymes has been transitory and
suggested to reﬂect an adaptation of the hepatocytes. In
this study, the diﬀerence in enzyme levels one month after
LCD compared to one month after GBP might reﬂect such
adaptation, as the daily average intake and composition of
nutrients supposedly were similar during the two periods.
In support of such notion, we have observed that patients
operated with gastric bypass without a preoperative LCD
treatment and examined one month after the operation
displayed elevated liver enzymes (unpublished).
Any caloric restriction causes a breakdown of fat, driven
by hormone-sensitive lipase inadipocytesand by lipoprotein
lipase in heart and skeletal muscles. Lipolysis in white
adipose tissue is mainly controlled by the antilipolytic
eﬀect of insulin and a stimulatory eﬀect of norepinephrine
released from sympathetic nerve endings and acting via
beta-adrenergic receptors [26]. Lipolysis is also inﬂuenced
by humoural factors such as circulating catecholamines,
growthhormone,thyroidhormones,andglucagon.Recently,
natriuretic peptides have been added to the list of lipolytic
hormones [27]. In this study, GH baseline concentrations
increased throughout and thereby conceivably contributed
to promote lipolysis. Increases in GH levels after GBP have
been described by us [28]a n do t h e r s[ 29]. The BNP levels
were unchanged duringtheLCDmonth while theywere seen
to increase during the GBP month. We are not aware of any
prior reports of BNP levels determined after gastric surgery.
In a recent report, centrally administered GLP-1 was
found to stimulate sympathetic ﬂow and lipolysis of body
fat [30]. An increased secretion of GLP-1 is a prominent
ﬁnding in patients who have been operated with gastric
bypass [4, 31]. Hypothetically, a central GLP-1 mechanism
might play a role for the enhanced lipolysis after GBP.
Glucagon stimulates glycogenolysis and fatty acid oxidation
in the liver and has been shown also to stimulate lipolysis
in adipocytes [32, 33]. In patients operated with GBP, a
remarkable response with a rise in glucagon following food
intake has been observed [34, 35]. Possibly, postprandial
increasesinglucagonlevelsmightcontributetotheenhanced
mobilization of body fat after GBP surgery.
In conclusion,the mechanism behind an enhanced lipol-
ysis after GBP seems multifactorial. The caloric restriction
imposed by the surgical procedure is the main driver of
lipolysis, to which altered gastrointestinal signalling, for
example, meal-stimulated increases in GLP-1 and glucagon,
and sympathetic nerve outﬂow to the adipose tissue in
autonomic nerves conceivably contribute. It is likely that
FFAsareutilizedasenergysourceinheartandskeletalmuscle
and lower the need for glucose, which in turn lowers insulin
secretion in the nonfed state and thereby promotes lipid
mobilization. Lipolysis might also bestimulated by increased
fasting levels of lipolytic hormones, for example, growth
hormone, BNP, catecholamines. An increased ﬂux of FFA
from adipose tissues depots would promote the maintained
triglyceride levelsin the liverone monthafter GBP. To obtain
further insights into the phenomenon of enhanced lipolysis,
studies of diurnal hormone and catecholamine dynamics
could be of interest.
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